Compare MIN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIN | BNR |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.9M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | MIN | BNR |
|---|---|---|
| Price | $2.48 | $16.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 398.1K | 29.9K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $2.18 |
| 52 Week High | $2.72 | $41.72 |
| Indicator | MIN | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 35.24 |
| Support Level | N/A | $15.61 |
| Resistance Level | $2.60 | $23.42 |
| Average True Range (ATR) | 0.03 | 1.24 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 34.64 | 4.49 |
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.